In solid cancers, high expression of the cellular prion protein (PrPC) is associated with stemness, invasiveness, and resistance to chemotherapy, but the role of PrPC in tumor response to radiotherapy is unknown. Here, we show that, in neuroblastoma, breast, and colorectal cancer cell lines, PrPC expression is increased after ionizing radiation (IR) and that PrPC deficiency increases radiation sensitivity and decreases radiation-induced radioresistance in tumor cells. In neuroblastoma cells, IR activates ATM that triggers TAK1-dependent phosphorylation of JNK and subsequent activation of the AP-1 transcription factor that ultimately increases PRNP promoter transcriptional activity through an AP-1 binding site in the PRNP promoter. Importantly, we show that this ATM-TAK1-PrPC pathway mediated radioresistance is activated in all tumor cell lines studied and that pharmacological inhibition of TAK1 activity recapitulates the effects of PrPC deficiency. Altogether, these results unveil how tumor cells activate PRNP to acquire resistance to radiotherapy and might have implications for therapeutic targeting of solid tumors radioresistance.
Subscribe to Journal
Get full journal access for 1 year
only $7.98 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Schulz A, Meyer F, Dubrovska A, Borgmann K. Cancer stem cells and radioresistance: DNA repair and beyond. Cancers. 2019;11. https://doi.org/10.3390/cancers11060862.
Span PN, Bussink J. the role of hypoxia and the immune system in tumor radioresistance. Cancers. 2019; 11. https://doi.org/10.3390/cancers11101555.
Zhou S, Zhang M, Zhou C, Wang W, Yang H, Ye W. The role of epithelial-mesenchymal transition in regulating radioresistance. Crit Rev Oncol Hematol. 2020;150:102961.
Bravard A, Auvré F, Fantini D, Bernardino-Sgherri J, Sissoëff L, Daynac M, et al. The prion protein is critical for DNA repair and cell survival after genotoxic stress. Nucleic Acids Res. 2015;43:904–16.
Du L, Rao G, Wang H, Li B, Tian W, Cui J, et al. CD44-positive cancer stem cells expressing cellular prion protein contribute to metastatic capacity in colorectal cancer. Cancer Res. 2013;73:2682–94.
Le Corre D, Ghazi A, Balogoun R, Pilati C, Aparicio T, Martin-Lannerée S, et al. The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. EBioMedicine. 2019;46:94–104.
Salvesen Ø, Tatzelt J, Tranulis MA. The prion protein in neuroimmune crosstalk. Neurochem Int. 2019;130:104335.
Martin-Lannerée S, Hirsch TZ, Hernandez-Rapp J, Halliez S, Vilotte J-L, Launay J-M, et al. PrP(C) from stem cells to cancer. Front Cell Dev Biol. 2014;2:55.
Ryskalin L, Busceti CL, Biagioni F, Limanaqi F, Familiari P, Frati A et al. Prion protein in glioblastoma multiforme. Int J Mol Sci. 2019;20. https://doi.org/10.3390/ijms20205107.
Manni G, Lewis V, Senesi M, Spagnolli G, Fallarino F, Collins SJ, et al. The cellular prion protein beyond prion diseases. Swiss Med Wkly. 2020;150:w20222.
Siberchicot C, Gault N, Déchamps N, Barroca V, Aguzzi A, Roméo P-H, et al. Prion protein deficiency impairs hematopoietic stem cell determination and sensitizes myeloid progenitors to irradiation. Haematologica. 2020;105:1216–22.
Berger ND, Stanley FKT, Moore S, Goodarzi AA. ATM-dependent pathways of chromatin remodelling and oxidative DNA damage responses. Philos Trans R Soc Lond B Biol Sci. 2017;372. https://doi.org/10.1098/rstb.2016.0283.
Wu Z-H, Wong ET, Shi Y, Niu J, Chen Z, Miyamoto S, et al. ATM- and NEMO-dependent ELKS ubiquitination coordinates TAK1-mediated IKK activation in response to genotoxic stress. Mol Cell. 2010;40:75–86.
Yang Y, Xia F, Hermance N, Mabb A, Simonson S, Morrissey S, et al. A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol. 2011;31:2774–86.
Santoro R, Carbone C, Piro G, Chiao PJ, Melisi D. TAK-ing aim at chemoresistance: the emerging role of MAP3K7 as a target for cancer therapy. Drug Resist Updat Rev Comment Antimicrob Anticancer Chemother. 2017;33–35:36–42.
Atkinson CJ, Kawamata F, Liu C, Ham S, Győrffy B, Munn AL, et al. EGFR and Prion protein promote signaling via FOXO3a-KLF5 resulting in clinical resistance to platinum agents in colorectal cancer. Mol Oncol. 2019;13:725–37.
Cheng Y, Tao L, Xu J, Li Q, Yu J, Jin Y, et al. CD44/cellular prion protein interact in multidrug resistant breast cancer cells and correlate with responses to neoadjuvant chemotherapy in breast cancer patients. Mol Carcinog. 2014;53:686–97.
Lee JH, Yun CW, Lee SH. Cellular prion protein enhances drug resistance of colorectal cancer cells via regulation of a survival signal pathway. Biomol Ther. 2018;26:313–21.
Wiegmans AP, Saunus JM, Ham S, Lobb R, Kutasovic JR, Dalley AJ et al. Secreted cellular prion protein binds doxorubicin and correlates with anthracycline resistance in breast cancer. JCI Insight. 2019;5. https://doi.org/10.1172/jci.insight.124092.
Zhuang D, Liu Y, Mao Y, Gao L, Zhang H, Luan S, et al. TMZ-induced PrPc/par-4 interaction promotes the survival of human glioma cells. Int J Cancer. 2012;130:309–18.
Kefayat A, Ghahremani F, Safavi A, Hajiaghababa A, Moshtaghian J. C-phycocyanin: a natural product with radiosensitizing property for enhancement of colon cancer radiation therapy efficacy through inhibition of COX-2 expression. Sci Rep. 2019;9:19161.
Buch K, Peters T, Nawroth T, Sänger M, Schmidberger H, Langguth P. Determination of cell survival after irradiation via clonogenic assay versus multiple MTT Assay-a comparative study. Radiat Oncol Lond Engl. 2012;7:1.
Bellingham SA, Coleman LA, Masters CL, Camakaris J, Hill AF. Regulation of prion gene expression by transcription factors SP1 and metal transcription factor-1. J Biol Chem. 2009;284:1291–301.
Déry M-A, Jodoin J, Ursini-Siegel J, Aleynikova O, Ferrario C, Hassan S, et al. Endoplasmic reticulum stress induces PRNP prion protein gene expression in breast cancer. Breast Cancer Res BCR. 2013;15:R22.
Mahal SP, Asante EA, Antoniou M, Collinge J. Isolation and functional characterisation of the promoter region of the human prion protein gene. Gene. 2001;268:105–14.
Weizman N, Shiloh Y, Barzilai A. Contribution of the Atm protein to maintaining cellular homeostasis evidenced by continuous activation of the AP-1 pathway in Atm-deficient brains. J Biol Chem. 2003;278:6741–7.
Watt NT, Routledge MN, Wild CP, Hooper NM. Cellular prion protein protects against reactive-oxygen-species-induced DNA damage. Free Radic Biol Med. 2007;43:959–67.
Meslin F, Hamaï A, Gao P, Jalil A, Cahuzac N, Chouaib S, et al. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Cancer Res. 2007;67:10910–9.
Gil M, Kim YK, Kim K-E, Kim W, Park C-S, Lee KJ. Cellular prion protein regulates invasion and migration of breast cancer cells through MMP-9 activity. Biochem Biophys Res Commun. 2016;470:213–9.
Liu X, Li F, Huang Q, Zhang Z, Zhou L, Deng Y, et al. Self-inflicted DNA double-strand breaks sustain tumorigenicity and stemness of cancer cells. Cell Res. 2017;27:764–83.
Qin K, Zhao L, Ash RD, McDonough WF, Zhao RY. ATM-mediated transcriptional elevation of prion in response to copper-induced oxidative stress. J Biol Chem. 2009;284:4582–93.
Fan Y, Cheng J, Vasudevan SA, Patel RH, Liang L, Xu X, et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes neuroblastoma to chemotherapy. Apoptosis Int J Program Cell Death. 2013;18:1224–34.
Guan S, Lu J, Zhao Y, Woodfield SE, Zhang H, Xu X, et al. TAK1 inhibitor 5Z-7-oxozeaenol sensitizes cervical cancer to doxorubicin-induced apoptosis. Oncotarget. 2017;8:33666–75.
Melisi D, Xia Q, Paradiso G, Ling J, Moccia T, Carbone C, et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst. 2011;103:1190–204.
Piro G, Giacopuzzi S, Bencivenga M, Carbone C, Verlato G, Frizziero M, et al. TAK1-regulated expression of BIRC3 predicts resistance to preoperative chemoradiotherapy in oesophageal adenocarcinoma patients. Br J Cancer. 2015;113:878–85.
Wang Z, Zhang H, Shi M, Yu Y, Wang H, Cao W-M, et al. TAK1 inhibitor NG25 enhances doxorubicin-mediated apoptosis in breast cancer cells. Sci Rep. 2016;6:32737.
Han MW, Lee JC, Choi J-Y, Kim GC, Chang HW, Nam HY, et al. Autophagy inhibition can overcome radioresistance in breast cancer cells through suppression of TAK1 activation. Anticancer Res. 2014;34:1449–55.
Iglesia RP, Prado MB, Cruz L, Martins VR, Santos TG, Lopes MH. Engagement of cellular prion protein with the co-chaperone Hsp70/90 organizing protein regulates the proliferation of glioblastoma stem-like cells. Stem Cell Res Ther. 2017;8:76.
Huang Y-WA, Zhou B, Wernig M, Südhof TC. ApoE2, ApoE3, and ApoE4 differentially stimulate APP transcription and Aβ secretion. Cell. 2017;168:427–441.e21.
The authors thank Guillaume Pitton for lentiviruses productions; Nathalie Déchamps for flow cytometric cell sorting, at the IRCM Flow Cytometry Shared Resource (established by equipment grants from DIM-Stem-Pôle, INSERM, Foundation ARC, and CEA); Marilene Lopes (Lab of Neurobiology and Stem Cells, Sao-Paulo, Brazil) for kindly providing the plasmid used for generating SH-SY5Y CRISPR KO cells; Sophie Mouillet-Richard, François Leteurtre and Jérôme Lebeau for providing colorectal, and breast cancer cell lines.This work was supported by the French National Electricity Company (EDF), the Transverse Division N°4 (Segment n°4 Radiobiology headed by Christophe Carles) and the Radiobiology Program (PRIONRAD) of the French Alternative Energies and Atomic Energy Commission (CEA).
Conflict of interest
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Bernardino-Sgherri, J., Siberchicot, C., Auvré, F. et al. Tumor resistance to radiotherapy is triggered by an ATM/TAK1-dependent-increased expression of the cellular prion protein. Oncogene 40, 3460–3469 (2021). https://doi.org/10.1038/s41388-021-01746-0